| Disease                                                     |                                                                           Key immune cells | Major molecular / immune mechanisms                                                                                                           | Simple symptoms                                                                        | Classic / established therapies                                                                                                                          |
| ----------------------------------------------------------- | -----------------------------------------------------------------------------------------: | --------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **Psoriasis**                                               |                                Dendritic cells, Th17/Th1 cells, keratinocytes, neutrophils | IL-23/IL-17 axis → keratinocyte hyperproliferation; TNF signaling                                                                             | Well-demarcated scaly erythematous plaques (skin)                                      | Topical steroids, phototherapy, methotrexate/cyclosporine; biologics (anti-TNF, anti-IL-17, anti-IL-23)                                                  |
| **Multiple Sclerosis (MS)**                                 |                  Autoreactive CD4 (Th1/Th17), CD8 T cells, B cells, microglia, macrophages | Autoimmune demyelination in CNS; blood–brain barrier breach; complement & cytotoxicity                                                        | Relapses of focal neuro deficits, sensory/motor impairment, visual problems            | High-dose corticosteroids (relapses), disease-modifying therapies: interferon-β, S1P modulators, anti-CD20 (rituximab/ocrelizumab), natalizumab          |
| **Crohn’s Disease**                                         |                                        Innate immune cells, Th1/Th17, B cells, macrophages | Barrier dysfunction, dysregulated mucosal immunity (NOD2, IL-12/23, TNF); chronic transmural inflammation                                     | Abdominal pain, diarrhea, weight loss, fistulas                                        | Aminosalicylates (limited), corticosteroids (induction), immunomodulators (azathioprine), anti-TNF, anti-IL-12/23                                        |
| **HIV → AIDS**                                              |                                CD4⁺ T cells (primary target), macrophages, dendritic cells | Lentiviral infection → progressive CD4 depletion, immune deficiency, opportunistic infections                                                 | Lymphadenopathy → opportunistic infections, weight loss, chronic fever                 | Combination antiretroviral therapy (ART); opportunistic infection prophylaxis                                                                            |
| **SLE (systemic lupus erythematosus)**                      |                                   B cells, plasmablasts, Tfh, plasmacytoid DCs, complement | Autoantibodies (anti-dsDNA), immune complexes → complement activation; type I IFN signature                                                   | Malar rash, arthritis, nephritis, cytopenias, photosensitivity                         | Hydroxychloroquine, corticosteroids, immunosuppressants (azathioprine, mycophenolate), biologics (belimumab), supportive care                            |
| **Aicardi–Goutières Syndrome (AGS)**                        |                                         Microglia, innate immune sensors, plasmacytoid DCs | Genetic defects in nucleic acid metabolism → chronic type I interferonopathy (sensing of self-nucleic acids)                                  | Early onset encephalopathy, intracranial calcifications, developmental delay           | Supportive; immunomodulation (JAK inhibitors) and symptomatic care (experimental)                                                                        |
| **COPA syndrome**                                           |                                                      T cells, B cells, innate immune cells | Defect in ER-Golgi transport → autoimmune/autoinflammatory phenotype often with elevated type I IFN                                           | Interstitial lung disease, arthritis, autoimmunity                                     | Immunosuppression (steroids, calcineurin inhibitors), targeted approaches (JAK inhibitors); lung transplant in severe ILD                                |
| **Alzheimer’s disease (microglia-related aspects)**         |                                               Microglia, complement components, astrocytes | Microglial activation, complement-mediated synapse pruning, TREM2 pathway; chronic neuroinflammation                                          | Progressive memory loss, cognitive decline                                             | Symptomatic drugs (AChE inhibitors, memantine); anti-amyloid / anti-tau immunotherapies (experimental); symptomatic/supportive care                      |
| **Autism Spectrum Disorder (ASD) — microglia associations** |                          Microglia (proposed role), peripheral immune cells (associations) | Associations of neuroimmune dysregulation in some cases (microglial activation/inflammation) — heterogeneous and incompletely understood      | Social-communication deficits, restricted/repetitive behaviors                         | Behavioral therapies (ABA), developmental interventions; no standard immunotherapy (research ongoing)                                                    |
| **Sepsis**                                                  |             Innate immune cells (neutrophils, macrophages), endothelial cells, lymphocytes | Dysregulated host response to infection → excessive cytokines, coagulopathy, immune paralysis/sequential hypo-inflammation                    | Fever/hypothermia, tachycardia, hypotension, organ dysfunction                         | Early antibiotics, source control, fluid resuscitation, vasopressors, organ support; adjunctive immunomodulation selective in trials                     |
| **COVID-19 (severe)**                                       |                                Epithelial cells, innate immune cells, T cells, neutrophils | Viral infection with possible hyperinflammation (cytokine storm), coagulopathy, impaired antiviral immunity                                   | Fever, cough, dyspnea → hypoxemia, ARDS in severe cases                                | Antivirals (where approved), dexamethasone for severe disease, supportive care, monoclonal antibodies (prophylaxis/early disease), vaccines (preventive) |
| **Rheumatic Fever**                                         |                                                       Cross-reactive T/B cells, antibodies | Molecular mimicry after Group A strep → immune cross-reaction against heart/striatum → carditis                                               | Fever, migratory polyarthritis, carditis, chorea (Sydenham)                            | Eradicate streptococcal infection (penicillin), anti-inflammatory therapy (aspirin, steroids), long-term prophylaxis                                     |
| **Rheumatoid Arthritis (RA)**                               | Synovial macrophages, fibroblast-like synoviocytes, Th17, B cells (autoantibodies RF/ACPA) | Autoantibody-associated chronic synovitis; TNF, IL-6, IL-1 pathways; joint erosion mediated by osteoclasts                                    | Symmetric peripheral polyarthritis, morning stiffness, joint erosions                  | NSAIDs, glucocorticoids (bridging), DMARDs (methotrexate), biologics (anti-TNF, anti-IL-6, anti-CD20)                                                    |
| **Rheumatic Heart Disease (RHD)**                           |                                     Result of post-streptococcal immune injury (T/B cells) | Chronic valvular damage from immune cross-reactivity after rheumatic fever                                                                    | Valvular regurgitation/stenosis, heart failure, arrhythmias                            | Secondary prophylaxis (penicillin), medical management of heart failure; valve repair/replacement surgery                                                |
| **Guillain–Barré syndrome (GBS)**                           |                             Peripheral nerve-targeting antibodies, complement, macrophages | Autoimmune peripheral demyelination (often post-infection); anti-ganglioside antibodies in subtypes → complement & macrophage-mediated injury | Rapidly progressive ascending weakness, areflexia, possible respiratory failure        | IV immunoglobulin (IVIG) or plasmapheresis, supportive respiratory care, rehab                                                                           |
| **Cancer (immune aspects)**                                 |                Cytotoxic CD8 T cells, NK cells, tumor-associated macrophages, Tregs, MDSCs | Immune evasion (PD-L1, CTLA-4, antigen loss), chronic inflammation, immunosuppressive tumor microenvironment                                  | Variable by tumor type — mass effect, organ-specific symptoms, constitutional symptoms | Surgery, chemo, radiotherapy; immunotherapies: checkpoint inhibitors (anti-PD-1/PD-L1, anti-CTLA-4), CAR-T, cytokine therapies, targeted small molecules |
